January 05, 2022

The Future of Due Diligence in Healthcare M&A

COVID-19 placed healthcare squarely in the center of everyone’s mind. From fledgling startups to large corporates, the healthcare industry is modernizing itself at lightning speed.

To make that happen, deal activity within healthcare has exploded at dizzying rates. R&D breakthroughs, point-of-care disruption, and strategic plays into digital health make the healthcare sector one rich with opportunity and risk. To manage that risk, staying on top of due diligence best practices is critical. In this whitepaper, we explore:

  • Current healthcare M&A due diligence benchmarks 
  • Trends reshaping the face of healthcare due diligence
  • An updated healthcare due diligence checkup list

Download the whitepaper and learn more. 

Ready to Get Started?

You may also like:

As the Tide Turns, What’s Next? H2 2022 Market Outlook

If 2021 was a high water mark for M&A, then 2022 is seeing the ebbing of the tide. In our latest report in association with PitchBook, Datasite assesses the new outlook for dealmakers.

The New State of M&A: Africa, Middle East & Turkey

Most Africa, Middle East & Turkey M&A practitioners believe new technologies should enable greater analytical capability, and security, in the due diligence process over the next five years. How else can technology help them and in what areas?

Deal Drivers: APAC Q1 2022

M&A activity across the APAC region as a whole slipped in Q1, which was to be expected after a record-setting 2021. It’s a trend that can be observed across geographic markets an is best understood as a reversion to the mean rather than a cause for concern at this stage. Learn more from our latest Deal Drivers report.